TG Therapeutics Soars on Positive Results for MS Treatment
TG Therapeutics (TGTX) - Get Report soared Thursday after the biopharma announced positive results from two global Phase 3 studies, evaluating ublituximab, the company's treatment of multiple sclerosis patients.
Shares of the New York-based company were skyrocketing nearly 42% to $42.04 in trading Thursday.